Antigangrenous effect of an odontological preparation.
Experiments were performed in order to compare the antigangrenous effect of Pyralvex Berna and its components (alcoholic salicylic acid solution and extractum rhei, resp.) with that of an antiphlogistic standard preparation (phenylbutazone). In this experimental model the tails of albino mice are put into water of 55 degrees C for 10 sec. This results in the loss of part of the tail within  the following days. In the present investigation, the tail of part of the animals was put into one of the solutions to be examined for 5 sec immediately after exposure to heat as well as on the following 5 days. In the controls 55.65% (on an average) of the original length of the tail were lost, in the animals treated with phenylbutazone 19.10% (on an average) and in the animals treated with Pyralvex 27.25% (on an average) were lost. Thus, the antigangrenous effect of Pyralvex was 77% of that of phenylbutazone. The statistical analysis of the results obtained in the 4th and 5th groups demonstrates that this effect is mainly due to extractum rhei, the antigangrenous effect of which is statistically not significantly different from the antigangrenous effect of Pyralvex (p greater than 0.4).
D000818:Animals; D000880:Anthraquinones / Q000008:administration & dosage / Q000494:pharmacology* / Q000627:therapeutic use; D000893:Anti-Inflammatory Agents; D004338:Drug Combinations; D005734:Gangrene / Q000188:drug therapy*; D051379:Mice; D010653:Phenylbutazone / Q000494:pharmacology; D012459:Salicylates / Q000008:administration & dosage / Q000494:pharmacology* / Q000627:therapeutic use; D013623:Tail
D000880:Anthraquinones; D000893:Anti-Inflammatory Agents; D004338:Drug Combinations; D012459:Salicylates; D010653:Phenylbutazone